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Current pharmacological and surgical treatments for Parkinson’s disease oﬀer symptomatic improvements to those suﬀering from
this incurable degenerative neurological disorder, but none of these has convincingly shown eﬀects on disease progression. Novel
approaches based on gene therapy have several potential advantages over conventional treatment modalities. These could be used
to provide more consistent dopamine supplementation, potentially providing superior symptomatic relief with fewer side eﬀects.
More radically, gene therapy could be used to correct the imbalances in basal ganglia circuitry associated with the symptoms of
Parkinson’sdisease,ortopreserveorrestoredopaminergicneuronslostduringthediseaseprocessitself.Thelatterneuroprotective
approach is the most exciting, as it could theoretically be disease modifying rather than simply symptom alleviating. Gene therapy
agents using these approaches are currently making the transition from the laboratory to the bedside. This paper summarises the
theoretical approaches to gene therapy for Parkinson’s disease and the ﬁndings of clinical trials in this rapidly changing ﬁeld.
1.Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder that will assume increasing clinical importance in
an ageing society, with an average age of onset between 60
and 65 years, but a peak incidence is found between the ages
of 70 and 79 years. The speciﬁc incidence is dependent on
the age structure of the population studied and is diﬃcult to
assess precisely but is around 17 per 100,000 according to a
systematic review in this area [1].
PD is classically characterised by the loss of striatal
dopaminergic neurons within the basal ganglia; however, the
underlying pathophysiology is very complex. Both excitatory
glutamatergic and inhibitory γ-aminobutyric acid pathways
(GABA) involved in basal ganglia regulation of movement
are aﬀected [2]. These changes lead to disinhibition of sub-
thalamic nucleus (STN) output, which in turn increases the
activity of excitatory projections to the internal globus palli-
dus (GPi) and substantia nigra pars reticularis (SNpr). The
net result is increased inhibitory outﬂow from the GPi and
SNpr to other basal ganglia nuclei, thalamus, and cortex,
leading to the typical motor features of PD [3]. Various ther-
apeutic approaches that target the STN or GPi have been
usedtoimprovemotorfunctioninPD,includingstereotactic
lesioning [4, 5], high frequency deep brain stimulation [6, 7]
and pharmacological silencing [8].
Dopamine replacementtherapies,suchaslevodopa, were
developed around ﬁfty years ago and still constitute the
mainstay of treatment for PD [9]. Patients generally respond
very well to this strategy initially, to the extent that failure to
respond to levodopa treatment should cause the physician to
question the veracity of the diagnosis. However, with long-
term treatment, the response to dopamine replacement ﬂuc-
tuates and “wearing oﬀ” phenomena or troubling dyskinesi-
as develop [10]. The Parkinson Study Group estimate that
over half of patients with early PD receiving levodopa devel-
op at least one of these side eﬀects during the ﬁrst two years
of treatment [10].2 Parkinson’s Disease
T h ep r o b l e m sw i t hl o n g - t e r ml e v o d o p at r e a t m e n th a v e
led to the search for new therapeutic strategies for PD. Phar-
macological agents such as dopamine agonists can be used
to delay the initiation of levodopa or as adjuvant therapies.
Similarly, catechol O-methyltransferase (COMT) inhibitors
are used in an adjuvant role. In more advanced disease, con-
tinuous subcutaneous infusions of apomorphine or intrad-
uodenally administered levodopa (Duodopa) can, to some
extent, address the problem of ﬂuctuations in clinical re-
sponse and improve PD symptom control.
The pharmacological and surgical therapies described
above aim to improve the symptoms of PD but none are
proven to have a signiﬁcant impact on the underlying disease
process with respect to either slowing disease progression or
restoring the aﬀected dopaminergic neurons. Gene therapy
has distinct potential advantages over conventional treat-
ment modalities for PD as it could theoretically be used to
preserve or restore dopaminergic neurons aﬀected by PD
through the action of neurotrophic factors [11, 12] or alter-
natively increase the availability of enzymes required for
dopaminesynthesis[13,14].Althoughthediseasemodifying
properties of these therapies remain to be proven, they could
potentially target the underlying pathophysiological imbal-
ancesandmayresultinmuchlessﬂuctuationinresponseand
a lower prevalence of dyskinesias than conventional phar-
macotherapy for PD. It should be highlighted that PD man-
ifests with additional clinical and paraclinical nonmotor fea-
tures (including sleep disturbance/fatigue, autonomic, gas-
trointestinal, neuropsychiatric, and sensory symptoms) [15,
16] which are unlikely to result from speciﬁc degeneration
of the dopaminergic pathways. Alternative therapeutic ap-
proaches will be required to address these issues.
2.GeneDelivery
The use of gene therapy to treat PD necessitates the use of a
suitablemethodofdeliveryforthesynthesisednucleicacid—
viral or nonviral. The choice of vector greatly inﬂuences the
technique used for delivery, as a peripherally administered
vector must be able to cross the blood-brain barrier with an
acceptable degree of tissue speciﬁcity. Alternatively, the sur-
gical techniques used for deep brain stimulation can be har-
nessed to deliver the vector directly to a speciﬁc brain region.
Nonviral techniques are technically and conceptually
m o r es t r a i g h t f o r w a r db u ta r el e s sw e l ls u i t e dt ot r e a t i n ga
chronic neurodegenerative disorder such as PD, due to the
short duration of gene expression that is typically achieved.
Low transfection rates mean that experiments using nonviral
vectors have often used multiple dose regimens [17]. This
poses particular problems for translation to human studies if
repeated intracerebral injections, with their associated risks,
are needed to achieve a meaningful clinical response. This
approach may still prove eﬀective, as seen in a recent study
using the human glial cell-derived neurotrophic factor
(GDNF) gene and a neurotensin polyplex nanoparticle vec-
tor in an animal model of PD, ﬁnding that a single intrac-
erebral injection of the agent may prove suﬃcient to induce
a biochemical and functional response [18]. Other nonviral
vector studies in animal models of PD have incorporated
region-speciﬁc ligands in order to maximise tissue speciﬁcity
using intravenous vector administration [17]. For example,
onegroup[19]hasusedTrojanhorseliposomesandamono-
clonal antibody to the transferrin receptor to facilitate trans-
portacrossthebloodbrainbarrier ofaperipherallyadminis-
tered therapeutic plasmid containing DNA for GDNF. They
alsoincorporatedthegenepromoterfortyrosinehydroxylase
(TH), a key enzyme in the synthesis of dopamine, to restrict
expression of the transgene to catecholaminergic neurons.
Viral vectors, derived from either DNA or RNA viral vec-
tors, are generally considered to be a more practical ap-
proach, with the potential to cause long lasting gene expres-
sion via episome formation or DNA integration into the host
genome. A range of diﬀerent types of viruses, each with dif-
ferent properties and advantages, have been exploited in the
search for a suitable vector for gene therapy in PD. These are
detailed below, with particular attention to adeno-associated
viruses which comprise by far the largest category of vectors
used in clinical trials to date.
3. AAV
Adeno-associated viruses are relatively simple 4.7 Kb single-
stranded DNA viruses from the Parvoviridae family [20].
They comprise two genes encoding capsid (cap)a n dv i r a l
replication (rep) proteins and inverted terminal repeat se-
quences, but require additional genes from other viruses
(e.g., adenovirus) for replication. AAVs are well suited to
gene therapy for PD as they are capable of inducing long-
term gene expression, usually via episome formation [21].
AAVs are also able to integrate into a speciﬁc site at chro-
mosome 19 of the human genome raising potential concerns
regarding insertional mutagenesis, although the frequency
with which integration occurs in vivo remains unclear [22,
23]. More than 100 AAV variants have been identiﬁed and
they are classiﬁed into nine genetic clades with diﬀering tis-
sue tropisms [24]. AAVs 1–10 have been used for gene
therapy vector production but AAV-2-derived vectors are the
best characterised and most frequently utilised serotype in
PD gene therapy studies.
One advantage of AAV-2, when administered locally, is
that it transduces only neurons within the central nervous
system and is particularly eﬃcient in brain regions known to
be involved in the pathophysiology of PD, such as the globus
pallidus and substantia nigra [22]. A recent rodent study
using AAV-2 as a viral vector found that following stereotac-
tic parenchymal injection, 97% of transgene expression was
restricted to the targeted subthalamic nucleus and no AAV
genomes were detected in recipient blood or cerebrospinal
ﬂuid,thoughasmallminorityofanimalshaddetectableAAV
genomes in nonbrain tissue [25].
Recent research additionally suggests that AAV-1, -5, and
-8 are also able to transfect basal ganglia neurons in a high-
ly eﬃcient and speciﬁc manner in nonhuman primates and
therefore these serotypes could be used in future gene thera-
pytrials[26].Inaddition, arecentstudyinvestigating theuse
of erythropoietin as a therapeutic agent for PD successfully
deliveredthegenetostriatalneuronsusingAAV-9inarodent
model (discussed below) [27].Parkinson’s Disease 3
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Figure 1: Triple transfection strategy for the in vitro production of
recombinant adenoassociated viruses (AAV).
One disadvantage of AAV is that approximately 80% of
humans exhibit antibodies to AAV-2, which potentially ad-
versely aﬀects AAV-2-mediated gene transfer—particularly
outside the CNS. In contrast, the utility of AAV-5 as a viral
vector appears to be unaﬀected by the humoral immune
response [28, 29]. It therefore seems likely that future human
trials of gene therapy for PD will not be limited to the AAV-2
serotype. There is also evidence for a cellular immune re-
sponse, which may also have implications for the eﬃciency
of transgene expression using AAV [30]. Another potential
problem inherent in using AAVs as vectors is the relatively
smallsize,limitingcapacityforinsertedDNAtoaround4kb.
AAVs have a very attractive proﬁle in terms of safety, in
addition to their tropism for basal ganglia neurons. AAV is
not associated with any human disease and the wild-type
v i r u si sr e p l i c a t i o nd e f e c t i v e[ 31, 32]. Three-plasmid systems
arenowwellestablishedandroutinelyusedtoproducehighly
puriﬁedAAVs,furtherimprovingtheirsafety[33](Figure 1).
4. Lentivirus
Lentiviruses are retroviruses that can eﬃciently infect divid-
ingandnondividingcells[22].Thisclassincludesthehuman
immunodeﬁciency virus (HIV), which has been studied ex-
tensively, and most lentiviral vectors are consequently based
on HIV [34]. HIV-1-derived vectors incorporate a transgene
between the long terminal repeats (LTRs) required for inte-
gration into the host genome. The HIV-1 env gene product
largely restricts the tropism of wild-type virus to CD4
containing cells. By substituting env for gene encoding other
viral glycoproteins, such as the vesicular stomatitis virus gly-
coprotein, the cellular tropism can be broadened or made
more speciﬁc to neurons [35, 36]. Speciﬁcity for neurons can
be further improved by the use of speciﬁc promoters such as
neuron-speciﬁc enolase or synapsin-1, while introduction of
the human glial ﬁbrillary acidic promoter increases speci-
ﬁcity for glia [37, 38].
The more recent two or three plasmid systems have in-
creased the safety proﬁle of lentiviral-based vectors but con-
cerns remain regarding the possibility of recombination ev-
ents producing a replication competent virus [39]. However,
the capacity of these vectors, of approximately 9kb, makes
themaveryattractiveoptionforfuturegenetherapyresearch
[40].
5. Adenovirus
Adenovirus was one of the ﬁrst viral vectors used successfully
in animal models of PD and contains a 36kb genome
comprised of double-stranded DNA [22, 41]. Wild-type ade-
novirus is frequently associated with mild respiratory tract,
gastrointestinal, and conjunctival infections in humans,
though rarer sequelae such as severe adenovirus pneumonia
can have a mortality exceeding 50% [42]. Early adenoviral
vectors were created using E1 or E3/E4 gene region deletions,
buttheseprovedunsatisfactoryduetothehostinﬂammatory
response and associated toxicity that occurred in vivo when
the remaining wild-type genes were expressed in the host
[43].
Newer“gutless”adenoviralvectorshaveretainedonlythe
inverted terminal repeats from the original wild-type viral
genome. They therefore have higher capacity and have been
shown to achieve transgene expression with reduced toxicity
[44]. However, this appears to have been achieved at the ex-
pense of lower transduction eﬃciency [45] and some innate
immune responses to the “gutless” adenoviral vectors persist
[46]. Some advantages of this group include the relative ease
ofscalingupproduction,incomparisontoAAV,forexample,
and robust gene expression [35, 47].
6.HSV
Herpessimplexvirusisa150kbdouble-strandedDNAvirus,
which as a result of its size has a far larger packaging capacity
than the viruses already described. In addition to a long-
lasting episomal latency, the viral vector is neurotropic—
the wild-type virus is associated with encephalitis, as well as
cold sores and corneal ulceration [48], and HSV-1 has been
shown to infect neurons [49]. HSV-1 vectors can be subdi-
vided into recombinant viral and amplicon vector systems.
Recombinant viral systems retain most of the wild-type ge-
nome, using homologous recombination to insert the re-
quiredforeigngene.Thissystemallowsforverylargegenesto
be inserted if all the wild-type genes were removed [22]. The
amplicon vector, in contrast, contains only a cis acting viral
origin of replication and packaging signal, with the genes
required for replication and virus production are supplied in
trans by a separate helper virus.4 Parkinson’s Disease
Table 1: An overview of the therapeutic approaches used in current clinical trials of gene therapy for Parkinson’s disease.
Therapeutic approach Vector Clinical trials
Increased dopamine biosynthesis
(i) AADC alone Adeno-associated virus Phase I [13, 60]
(ii) AADC, TH, and GCH-1 Lentivirus Phase I/ II in progress [54]
Modulation of excitatory and
inhibitory basal ganglia activity
(i) GAD Adeno-associated virus Phase I and II [61, 62]
Neurotrophic support
(i) GDNF Adeno-associated virus License obtained to develop, no published clinical trials [63]
(ii) Neurturin Adeno-associated virus Phase I and II [12, 59]
AADC, aromatic amino acid decarboxylase; GAD, glutamic acid decarboxylase; GCH-1, GTP-cyclohydrolase-1; GDNF, glial cell line-derived neurotrophic
factor; TH, tyrosine hydroxylase.
Animalstudiessuggestthatlonglastingtransgeneexpres-
sion in neurons can be achieved using HSV-1 amplicons and
the use of speciﬁc promoters, for example, those for tyrosine
hydroxylase, can increase transduction speciﬁcity [50–52].
There remain some concerns over safety and toxicity of
HSV-derived vectors, but research to address these issues is
ongoing [35, 53].
7. Gene Therapy for Parkinson’s Disease
Several complex and interrelated issues need to be addressed
in attempting to bring gene therapy for PD from the
laboratory to the bedside. The most fundamental of these
issues is the selection of a suitable therapeutic target; PD has
a complex pathophysiology that is by no means fully under-
stood and involves multiple brain structures and signalling
pathways. There are three broad approaches to selection of
a therapeutic target. The ﬁrst and most straightforward of
these is to increase dopamine levels in the basal ganglia
by the introduction of transgenes encoding enzymes or cell
signalling proteins involved in dopamine production or reg-
ulation. The key enzymes involved in dopamine metabolism
are tyrosine hydroxylase (TH), aromatic amino acid decar-
boxylase(AADC),andGTP-cyclohydrolase-1(GCH-1).Ani-
mal studies using this approach have been promising and
human phase I/II trials of a lentiviral vector containing genes
encoding all three key enzymes (ProSavin), are ongoing [14,
54, 55]. The second approach aims to modulate basal ganglia
circuitry aﬀected by PD, for example, by increasing levels
of GABA to counteract the overactivity of the subthalamic
nucleusobservedinthiscondition.Bothoftheseapproaches,
if successful, are likely to result in symptomatic relief for
patients rather than an alteration in disease progression.
The ﬁnal approach to choosing a therapeutic target aims
t ou s en e u r o t r o p h i cf a c t o r s ,s u c ha sb r a i n - d e r i v e dn e u r o -
t r o p h i cf a c t o r( B D N F )[ 56, 57], glial cell line-derived neuro-
trophic factor (GDNF) [11, 58]o rn e u rt u r i n[ 59], to prevent
the death of dopaminergic neurons. This third approach
could potentially be disease modifying, in addition to any
symptomatic beneﬁt obtained. An overview of therapeutic
strategiesusedinclinicaltrialsofgenetherapyforPDisgiven
in Table 1.
8. Therapeutic Targets, Agents, and
Approaches for GeneTherapy in PD
8.1. Aromatic Amino Acid Decarboxylase. Aromatic amino
acid decarboxylase (AADC) is an enzyme responsible for the
production of dopamine from endogenous or exogenous
levodopa. Patients with PD require increasing doses of exog-
enous levodopa to control their symptoms as the disease
progresses and it has been suggested that AADC activity
may be reduced in PD. Therefore increasing the activity of
this enzyme using gene therapy may reduce both the symp-
toms of PD and the amount of levodopa required to con-
trol them, perhaps also alleviating the side eﬀects of pro-
longed levodopa therapy [64]. The validity of this proposed
therapeutic approach—targeting decarboxylase deﬁciency—
is not absolutely established, as there is evidence suggesting
that dopamine is eﬃciently decarboxylated in 5-hydroxy-
tryptophan (5-HT) immunoreactive neurons [65]. Similarly,
it is quite commonly observed in clinical practice that pa-
tients with quite advanced PD still beneﬁt from the use of
low individual doses of oral levodopa, which would imply
that decarboxylase deﬁciency is not a major issue.
Nonetheless, several preclinical and clinical studies have
been published, producing interesting results. Experiments
in rhesus monkeys with hemiparkinsonism induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) show
that basal ganglia injection of AAV-AADC induced increased
AADC activity in vivo and increased immunostaining for
AADC, as well as improving dopamine to levodopa ratios
[64]. Improvements in AADC activity, sustained transgene
expression, lower levodopa requirements, and improved
functional outcomes persist up to 8 years after viral injection
[66, 67]. Outcomes from these animals at eight years provide
reassurance as to the safety and lasting eﬃcacy of this ap-
proach in a primate model of PD [67].
A subsequent phase I study using bilateral intraputam-
inal AAV-AADC injections in patients with moderate to
severe PD found a 30% increase in uptake of an AADC tracer
[13]. There was also some improvement in 6-month UPDRS
scores (both on and oﬀ medication), and 3 participants were
able to reduce their maintenance dose of levodopa, although
there was no control group in this study and results must
therefore be interpreted cautiously.Parkinson’s Disease 5
Subsequently, a second group comprising a further ﬁve
patients were recruited to the phase I study and treated with
a slightly higher dose of AAV-AADC (3 × 1011 rather than 9
× 1010 vector genomes) [60]. UPDRS scores in both the “on”
and “oﬀ” states were signiﬁcantly reduced overall, with
UPDRS scores showing a more signiﬁcant reduction in the
high-dose group than in the low-dose group, suggesting a
potential dose-response relationship. The patients reported
signiﬁcant reductions in “oﬀ” time and a nonsigniﬁcant re-
duction in the levodopa dose required to control symptoms
was observed in eight patients. Worryingly, three of the 10
subjects studied in total developed intracerebral haemor-
rhages. While those conducting the study suggest these relate
totheneurosurgicalprocedureusedforvectordeliveryrather
than the AAV-AADC itself, it nonetheless contributes to the
perception of increased risk associated with this treatment
modality when compared to conventional pharmacological
therapies. Two otherwise eligible participants were excluded
from the study due to raised antibody titres to AAV, high-
lighting the concern felt regarding potential immune re-
sponses against AAV in this type of clinical trial.
8.2. Tricistronic Gene Therapy with AADC, GCH-1, and TH.
The in vivo chemical synthesis of dopamine begins with the
conversion of L-tyrosine to levodopa by TH, and then the
levodopa is converted to dopamine by AADC. GCH-1 is a
rate limiting enzyme in the synthesis of a cofactor for TH
called tetrahydrobiopterin. In PD this synthetic process may
be deﬁcient at several diﬀerent points and replacement of a
single enzyme may not be suﬃcient to achieve a clinical re-
sponse. This has led to attempts to intervene at multiple
levels using a lentiviral vector containing genes encoding all
three key enzymes required for dopamine synthesis [14].
An early study using a 6-hydroxydopamine (6-OHDA)
treated rat model of PD found that the single lentiviral
vector was able to successfully transduce all three enzymes
and this led to signiﬁcant functional improvement in motor
asymmetry [14]. A subsequent study in nonhuman primates
with MPTP-induced parkinsonism found that the same
tricistronic lentiviral vector restored extracellular dopamine
levels within the striatum and also corrected functional mo-
tor deﬁcits for the following 12 months without inducing
dyskinesias [55]. Phase I/II human trials using Prosavin, the
aforementioned lentiviral vector containing genes for TH,
GCH-1, and AADC, are in progress. Preliminary data from
the manufacturer suggest that the safety proﬁle and func-
tional response are encouraging, though peer-reviewed out-
come data are not yet available.
8.3. GAD. Glutamic acid decarboxylase (GAD) is the key
enzyme involved in the synthesis of the inhibitory neuro-
transmitter GABA from excitatory glutamate. PD is associ-
ated with hyperactivity of the subthalamic nucleus as a con-
sequence of reduced activity in inhibitory nigrostriatal pro-
jections [68, 69]; therefore delivery of the gene encoding
GAD could increase local GABA production within the sub-
thalamic nucleus, restoring equilibrium between these path-
ways.GADexistsintwogeneticallydistinctisoforms,GAD65
and GAD67, with diﬀering anatomical and subcellular dis-
tributions, as well as diﬀering enzymatic properties [70–72].
An early in vitro study used two recombinant AAV con-
structs, encoding GAD65 and GAD67, to transduce CNS cell
lines leading to transcription of both genetic isoforms and
long-term GAD expression [73]. A subsequent in vivo study
using rats found that injection of AAV/GAD65 or AAV/
GAD67 with green ﬂuorescent protein (GFP) into the STN
led to long-term expression in the STN in both cases with
cellular distributions as predicted for the diﬀerent isoforms
[74]. Electrophysiological recordings were made during the
experiment, with a stimulatory electrode placed in the sub-
thalamic nucleus and microdialysis probes and recording
electrodes in the SNpr. These revealed that AAV/GAD65-
treatedratsshowedafourfoldstatisticallysigniﬁcantincrease
in GABA release following STN stimulation and single unit
recording from SNpr demonstrated a signiﬁcant shift in
electrophysiological responses to STN stimulation in AAV/
GAD65-treated rats compared to controls, with a greater
proportion of inhibitory responses to STN stimulation in the
former group.
In addition, one group of rats in this study were treated
with direct STN injection of AAV/GAD65 prior to 6-OHDA
lesioning of midbrain dopaminergic circuits in the median
forebrain bundle [74]. The animals showed signiﬁcant im-
provementsinseveralbehaviouralmeasuresofdopaminergic
deﬁcit and locomotion, but also had increased survival of
TH positive dopaminergic neurons, in comparison to con-
trols injected with GFP or saline prior to lesioning. The be-
havioural improvements with AAV/GAD65 in the 6-OHDA
rat model of PD have been replicated in a subsequent study,
but this did not provide any further evidence to support a
neuroprotective eﬀect of GAD65 transduction on dopamin-
ergic neurons [75].
FurtherstudiesusedamacaquemodelofPDwithcarotid
injection of MPTP to induce hemiparkinsonism to study the
eﬀects of subsequent STN injection of AAV/GAD in compar-
ison to control GFP injection [76]. They found that AAV/
GAD-treated hemiparkinsonian macaques showed signiﬁ-
cant improvements in clinical measures of parkinsonism
over 56 weeks with an associated signiﬁcant increase in ipsi-
lateral ﬂuorodeoxyglucose positron emission tomography
(FDG PET) activity, in comparison to controls. The use of
AAV/GAD in this primate study raised no new safety con-
cerns and the vector was able to transduce long-term GAD
expression, as conﬁrmed by histological analysis. A recent
rodent study using AAV2/GAD has provided further evi-
dence of safety, ﬁnding that 97% of vector genomes were
restricted to the ipsilateral STN following direct STN infu-
sion of the vector, and there was no discernible detrimental
eﬀect on animal health or behaviour [25].
These encouraging results in animal studies led Kaplitt
and coworkers to conduct the ﬁrst clinical trial of gene ther-
apy for an adult neurodegenerative disorder [61]. This open
label phase I study used stereotactic unilateral STN injection
of an AAV-2 serotype viral vector encoding human GAD65
or GAD67 under control of a cytomegalovirus (CMV) pro-
moter. Twelve patients with PD with Hoen and Yahr stage 3
or greater and signiﬁcant motor ﬂuctuations were recruited6 Parkinson’s Disease
and each received a single injection of 50μL of viral vector in
the most symptomatic hemisphere. As the main aim of the
study was to assess safety and tolerability, a range of concen-
trations of vector between 1 × 1011 and 10 × 1011 was used.
Over a followup period of at least 12 months no adverse
events related to the trial intervention were recorded, no pa-
tient withdrew from the study, and no patient was lost to
follow-up. While this study was neither blinded nor designed
toestablisheﬃcacy,signiﬁcantimprovementsinUniﬁedPar-
kinson’s Disease Rating Scale (UPDRS) motor scores were
observed in both the “on” and “oﬀ” states, with this eﬀect
persisting at 12 months. FDG PET demonstrated signiﬁcant
reduction in thalamic metabolism in treated patients on the
ipsilateral side only, with an associated increase in metab-
olisminthesupplementarymotorcortexthatcorrelatedwith
improvements clinical outcome measures.
The results of a phase II double-blind randomised con-
trolled trial of AAV2/GAD in 45 patients with advanced lev-
odopa responsive PD have recently been published [62]. The
intervention used bilateral stereotactic infusion of AAV2/
GAD into the subthalamic nucleus, while participants in the
control arm received an elaborate sham surgical procedure.
While both patient groups had signiﬁcantly lower UPDRS
motor scores at 6 months, the reduction in motor score was
signiﬁcantly greater in the intervention group than controls.
In addition, some secondary outcome measures such as the
UPDRS global score, also signiﬁcantly improved in the in-
tervention group compared to controls. One serious adverse
event occurred when a patient in the intervention group
developedbowelobstruction,thoughthiswasnotthoughtto
be related to the intervention. Less serious side eﬀects that
weremorefrequentintheinterventiongroupincludedhead-
ache and nausea. Overall, the phase II trial of AAV2/GAD
provides substantial support for both the eﬃcacy and the
safety of this approach in patients with PD.
8.4. GDNF. Glial cell line-derived neurotrophic factor was
ﬁrst characterised nearly two decades ago as a neurotrophic
factor for embryonic rodent midbrain dopaminergic neu-
rons, promoting their survival in vitro and increasing do-
pamine uptake in TH-positive neurons without altering
uptake of serotonin or GABA [77]. The authors realised its
potential application in the treatment of PD and a subse-
quentinvivostudyinamousemodelofPDfoundthatdirect
injection of GDNF into the substantia nigra or striatum re-
sulted in a relative increase in dopaminergic nerve ﬁbre
density and improvements in motor behaviour regardless
of whether the GDNF was administered before or after the
MPTP used to induce parkinsonism [78].
Related experiments used a replication defective adeno-
virus (Ad) vector to deliver the gene encoding human GDNF
as a direct injection near to rat substantia nigra in vivo,p r i o r
to lesioning with 6-OHDA [41]. Survival of dopaminergic
neurons was signiﬁcantly increased in those rats treated
with the Ad/GDNF vector compared to controls; however,
transgene expression for both GDNF and the LacZ promoter
( u s e da sat r a n s g e n ei nac o n t r o lg r o u p )w a sr e d u c e do v e r
the four week follow-up period of the study, raising doubts
about longer-term eﬃcacy of transgene expression. In addi-
tion, all animals treated with the Ad vector had localised
reactions at the injection site and this eﬀect was observed in
both the Ad/GDNF and the Ad/LacZ groups, suggesting it
relates to the vector or injection method rather than choice
of transgene. Other studies used a lentivirus vector to deliver
the GDNF gene by stereotactic striatal and substantia nigra
injection in vivo in rhesus monkeys one week prior to MPTP
treatment [11]. This resulted in an increase in the number of
TH-positive dopaminergic neurons in comparison to con-
trols. In addition, the rhesus monkeys treated with the len-
tiviral vector encoding GDNF performed better in behav-
ioural outcome measures than controls and demonstrated
increased and more symmetrical ﬂuorodopa uptake in the
striatum in FDG PET scans. Transgene expression of GDNF
using this lentiviral approach was sustained at 8 months and
there were no issues with host inﬂammatory responses.
In 2008, Amsterdam Molecular Therapeutics announced
that they had acquired a license from Amgen to develop an
AAV-based vector to deliver the GDNF gene as a potential
new therapy for PD [63], but no clinical trial results in hu-
mans have been published using this approach. Future hu-
man trials of gene therapy using GDNF for PD will need to
take into account the experience of clinical trials of direct
recombinant GDNF infusions in PD. Unfortunately, while
theinitialopenlabeltrialsinthisareawereencouraging,with
signiﬁcant reductions in UPDRS oﬀ scores in patients who
had received the intervention, the ﬁndings were not repli-
cated in a phase I/II double-blind randomised controlled
trial and subsequent studies found that the clinical eﬀect on
UPDRS scores in the open label study was not sustained a
year after treatment withdrawal [79–82]. This highlights the
importance of incorporating appropriate control groups and
suitable lengths of patient followup into the experimental
design, particularly as demonstration of sustained eﬃcacy
(over years) will be needed for this approach to become an
established clinical therapy.
8.5. Neurturin. Neurturin (NTN) is a neurotrophic factor
which was noted to both share structural similarities to
GDNF and to share the ability of GDNF to promote the
survival of dopaminergic neurons in vitro [83]. Neurturin
was subsequently noted to share receptors and signal trans-
duction pathways with GDNF, providing a putative mech-
anism for its neurotrophic eﬀect [84]. In vivo experimen-
tation in rats found that NTN mRNA is expressed during
development in the ventral midbrain and striatum, and in
addition can increase survival of mature dopaminergic neu-
rons when injected directly into the substantia nigra prior
to lesioning with 6-OHDA [85]. Furthermore, injection of
NTN directly into the striatum of intact adult rats led to
functional overactivity of nigral dopaminergic neurons [85].
In the MPTP primate model of PD, stereotactic injection
into the striatum and substantia nigra of an AAV vector
containing a gene encoding NTN four days after induction
of parkinsonism resulted in preservation of nigral neurons
relative to controls [86] .T h er h e s u sm o n k e y st r e a t e dw i t h
AAV-NTN (also known as CERE-120) showed an 80–90%Parkinson’s Disease 7
reduction in motor impairment from 4 months after treat-
ment to the end of the study at 10 months. Subsequently
published data found no adverse eﬀects, such as neurotox-
icity, and sustained NTN expression up to 12 months after
AAV-NTN treatment [87, 88].
Following these encouraging animal studies, 12 patients
with PD for at least 5 years underwent bilateral stereotac-
tic intraputaminal injections of AAV serotype 2-neurturin
(AAV2-NTN)inanopen-labelphaseIstudy[59].Duringthe
procedure and the 1-year follow-up period no serious ad-
verse events occurred; however, one patient developed an air
embolus related to the surgical intervention itself. The only
adverse events the authors felt could potentially be attributed
to the AAV2-NTN were three cases of dyskinesias on medi-
cation and one patient who developed hallucinations. How-
ever, there were more frequent complications, such as head-
ache occurring in eight patients, which the authors attribute
to the surgical intervention. While these are not strictly rel-
evant to the safety of AAV2-NTN, these do need to be taken
into consideration when comparing the risks and beneﬁts of
gene therapy versus conventional medical management in
future eﬃcacy (phase III) trials. Secondary outcome mea-
sures of eﬃcacy were encouraging, with signiﬁcant reduc-
tions in oﬀ-medication UPDRS motor scores at 12 months
after intervention compared to baseline.
The results of a phase II double-blind randomised con-
trolled trial of intraputaminal stereotactic AAV2-NTN injec-
tionversusshamsurgerywasrecentlypublished[12].Thirty-
eight patients were randomised to the intervention arm and
20 patients to sham surgery and participants were assessed at
three monthly intervals until the ﬁnal patient had completed
one year of followup. Unfortunately, there was no signiﬁcant
diﬀerence in the primary outcome measure, the reduction in
UPDRS oﬀ-medication motor score at 12 months, between
the control and intervention groups (P = 0.91). How-
ever, secondary outcome measures demonstrated signiﬁcant
improvements in the mental subscale of the UPDRS in the
“oﬀ” state and daily living component in the “on” state of
the UPDRS, in addition to signiﬁcant improvements in the
PDQ-39 single index score. None of the secondary outcome
measures assessed favoured the control group. There was no
signiﬁcant diﬀerence in FDG PET scans at baseline and 12
months between control and intervention groups. While the
lack of eﬃcacy in the primary outcome measure is disap-
pointing,asubgroupofpatientswhowerefollowedupfor18
months had a moderate but signiﬁcant reduction in UPDRS
score at this time point [89]. This perhaps suggests that
longer follow-up periods may be required to discern eﬃcacy
in the treatment group, particularly if the mechanism of
action is neuroprotective.
Thirteen of the 38 patients in the intervention group ex-
perienced adverse events, compared with four of the 20 con-
trolpatients[12].TwopatientsintheAAV2-NTNgroupdied
during the follow-up period—one suﬀered a myocardial in-
farction and the other a pulmonary embolus—neither of
which were felt to be directly related to AAV2-NTN. Three
patients in the AAV2-NTN group developed tumours com-
pared to two patients in the control group. The tumours
in the intervention group comprised one patient with
glioblastoma (found in retrospect to be present on baseline
imagingstudies),onewithoesophagealadenocarcinomaand
one with adenocarcinoma of the prostate. In all cases biopsy
tissue was negative for AAV2-NTN when tested using quan-
titative PCR. The most common side eﬀects occurring more
frequently in the intervention group than the control group
were headache and nausea.
Recent postmortem studies using brain tissue from two
patientswhodiedfromunrelatedcauseshaveconﬁrmedthat
AAV2-NTN gene therapy increased neurturin expression in
human participants with PD [90]. However, there were dif-
ferences in the pattern of protein expression in human post-
mortem brain tissue as compared to that found in the pre-
clinical primate AAV2-NTN studies. Most notable, perhaps,
is the lack of neurturin expression in the cell bodies of sub-
stantia nigra pars compacta (SNpc) in human brain, in con-
trast to the robust expression of neurturin and increased TH
immunoreactivity primates also treated with AAV2-NTN.
These results may have occurred because the time-frame
between intervention with AAV2-NTN and death was too
short in the patients whose brain tissue was studied (seven
weeks in one case) or because of the inability of the MPTP
primate model to accurately reﬂect the pathophysiological
mechanisms that occur in PD. The failure to achieve signif-
icant retrograde transport of neurturin from the striatum
to the SNpc—in contrast to previous primate studies—was
particularly marked. Although this could have resulted from
technical diﬀerences in tissue processing, it was thought
more likely that these resulted from a deﬁciency of axonal
transport of the bioactive agent in the studied PD cases. This
phenomenon has been postulated to exist in a range of neu-
rodegenerative disorders (amyotrophic lateral sclerosis and
Alzheimer’s disease, e.g.), and may not be manifest in animal
models of PD. The observed axonal transport deﬁciency was
hypothesizedtoaccountforthelackofprimaryendpoint(12
month) therapeutic eﬃcacy of AAV2-NTN in advanced PD
patients. As a consequence, the ongoing phase II trials of this
agent include protocols involving higher dosages of AAV2-
NTN and/or two injection sites in each SNpc. The clinical
consequences of these modiﬁed protocols will be of great
interest once the trials conclude.
8.6. Alternative Strategies. As mentioned above, a recent
study made use of an AAV-9 vector to deliver the gene for
human erythropoietin (Epo) by direct injection into the
striatum of 6-OHDA lesioned rats [27]. The authors found
that robust expression of human erythropoietin was present
for 10 weeks, but also that nigral dopaminergic cells were
protected from 6-OHDA-mediated toxicity and the treated
rodents showed associated improvements in behavioural
outcomes. This oﬀers a new potential neuroprotective target
for gene therapy in PD that clearly warrants further inves-
tigation. However, one potential problem also noted in this
rodent study is that striatal injection of AAV-9/Epo led to
increased numbers of peripheral erythrocytes. If signiﬁcant
polycythaemiaweretooccurinhumans,itcouldputpatients
at increased risk of complications, potentially including
ischaemic heart disease or stroke.8 Parkinson’s Disease
Our increasing appreciation of genetically deﬁned par-
kinsonian syndromes [91], particularly found in signiﬁcant
numbers in speciﬁc ethnic groups and familial PD patient
populations, has led to the concept of developing gene ther-
apeutic approaches designed to correct the eﬀects of disease
causing mutations. Both dominant (particularly LRRK2 as-
sociated) and recessive (including parkin, PINK1, and DJ-1
associated) forms of PD have been identiﬁed and the clinical
phenotype characterised in detail.
Mutations in parkin—an E3 ubiquitin-protein ligase—
result in reduced enzymatic activity of the protein, poten-
tially leading to neuronal cell death in the context of a range
of cytotoxic insults. Parkin gene therapy has been developed,
using either AAV or lentiviral approaches, showing potential
eﬃcacy in the alpha-synuclein overexpression rat and ma-
caque models of PD [92–94] and more recently in an MPTP
mouse model of PD [95].
Therapies designed for the other well-characterised
forms of recessive PD—resulting from mutations in PINK1
or DJ-1—are at an earlier stage of study and development.
It is postulated that the relevant mutations result in loss of
function of the protein and current research is principally
aimed at characterising the pathological results. In the case
of DJ-1 for example, knock-down studies in mice suggest
thatreducedexpressionoftheproteinsubjectsdopaminergic
neurons in the SNpc (which appear to be inherently prone to
oxidative stress due to their autonomous pacemaker activity)
to further increased oxidative stress [96] and cytotoxicity.
In a study examining the eﬀects of AAV-delivered Parkin or
DJ-1 on MPTP-lesioned mice, either agent led to increased
dopaminergic neuronal survival, but neither agent prevented
striatal dopamine depletion [97]. These intriguing ﬁndings
will require further investigation.
RNAinterference(RNAi)techniquesalsooﬀerpromising
novel therapeutic strategies for PD. Leucine-rich repeat kin-
ase 2 (LRRK2) mutations are thought to cause 10% of famil-
ial PD, in an autosomal dominant fashion, and 2-3% of spo-
radic PD, likely via gain of function mutations. RNAi tech-
niques could theoretically be used to silence expression of
alleles containing the LRRK2 mutation without reducing ex-
pression of wild-type allelic LRRK2. A recent study used
RNAi in vitro to achieve eﬃcient allele-speciﬁc targeting of
two LRRK2 mutations known to occur in PD, though tar-
geting of a third mutation was much less eﬃcient [98]. It
may in the future be possible, and perhaps more eﬀective,
to target speciﬁc genetic mechanisms associated with PD in
a particular individual in this manner, where such genetic
defects and predispositions are identiﬁable.
9. Design of ClinicalTrials of Gene Therapy in
Parkinson’sDisease
Several complex interrelated issues have to be addressed in
thedesignofclinicaltrialsofgenetherapyforPD.Theseneed
to reﬂect the relative lack of clinical experience with gene
therapy in comparison with other treatment modalities and
the limited ability of animal models to predict outcomes of
gene therapy in humans [89, 99]. Concerns about the safety
of trialing gene therapy for PD in humans have led to in-
volved debates as to whether relevant transgenes should be
placedunderthecontrolofcellspeciﬁcand/orinduciblepro-
moters. At ﬁrst glance, the theoretical advantages of directed
and inducible gene expression would appear obvious, and a
number of preclinical experiments have used the TH pro-
moter to direct gene expression to dopaminergic cells. Using
this approach is not entirely straightforward, however, re-
quiring additional genetic engineering and evaluation. The
larger size of the TH promoter (approximately 2.5kb in size
as compared to ∼600bp for CMV) could theoretically be an
issue with AAV-based constructs in which genetic capacity
is relatively limited. Furthermore, the eﬀectiveness of a ther-
apy designed to promote cell survival (such as GDNF or
neurturin) could be reduced if gene delivery and expression
is limited to dopaminergic cells that already dead or dying.
It may be more therapeutically eﬀective for genes to be ex-
pressed in a broad range of cells, with the agent secreted and
acting in a paracrine manner.
The theoretical advantages in using vectors with induci-
ble promoters, typically using speciﬁc antibiotic agents (such
as tetracycline/doxycycline) to drive expression, are obvious,
as their expression could be halted if safety concerns arose
in the medium or longer term. At present, there is relatively
limited in vivo data relating to this approach, in contrast to
the large number of patients who have participated in clin-
ical trials of (noninducible) AAV-based gene therapy, for
either PD or for other diseases such as Alzheimer’s or Can-
avan disease, without any major safety concerns being raised
[12, 59, 62, 100, 101]. This has led some to conclude that
the continued use of better-established noninducible AAV-
based gene therapies may actually be safer—based on
the availability of empirical evidence available—than using
novel, less well-evaluated, regulatable promoter mechanisms
[102].
PD is a heterogenous condition and most clinical trials
have excluded older patients with PD and those with demen-
tia, as well as having inclusion criteria that limit the trials to
those with more severe disease. The trial populations used
may not be representative of the general population of
patients with PD in the community as a whole. In addition,
it is clearly important to have a suitable control population
who undergo blinding where possible, including sham surgi-
cal procedures [99], as some gene therapy trials have dem-
onstrated positive eﬀects in open label phase I studies but
no signiﬁcant beneﬁt in the same outcome during a double-
blind controlled phase II study [12, 59].
Thechoiceofoutcomemeasureisalsoproblematic;most
studies—which largely aim to treat the dopaminergic deﬁ-
ciency of PD—have used the motor component of the
UPDRS score, but this neglects eﬀects on the nonmotor
symptoms that are often most problematic in late PD. While
the UPDRS is likely to remain the major source of outcome
data, some authors have highlighted the utility of collecting
additional data to ﬁnd out about other outcomes valued
highly by patients themselves [99]. There is unfortunately no
objective biomarker at present that has the validity and re-
liability to be used as a primary outcome measure,
though several studies use FDG PET or SPECT studies asParkinson’s Disease 9
a supplementary outcome measure of dopaminergic system
functioning [12, 99].
The design of therapeutic gene and its hypothesised ther-
apeutic mechanism should also have a signiﬁcant impact
on study design. For example, a gene therapy aiming to in-
crease release of dopamine in order to achieve symptomatic
improvements for PD patients may have observed eﬃcacy
overamuchshorterperiodthanagenetherapystrategyhop-
ing to achieve neuroprotection. Furthermore, those gene
therapies aimed at preserving greater numbers of dopamin-
ergic neurons or improving their functional ability may have
the greatest eﬃcacy in patients with early PD while there
are a greater proportion of SNpc dopaminergic neurons still
remaining, yet those with early PD have not been included in
any of the clinical trials of gene therapy to date. Including
those with early PD in trials also poses problems in itself
because of the lack of a “gold-standard” diagnostic test, the
absence of which may increase the heterogeneity of the study
groupbyunwittinglyincludingthosewhohaveanalternative
diagnosis.Futurestudieswillneedtotakegreatcareinselect-
ing patients with a deﬁned and where possible homogenous
range of “on” and/or “oﬀ” scores—as patients with persist-
ently high “on” scores may not beneﬁt signiﬁcantly from a
therapy designed to address dopaminergic deﬁciency. Simi-
larly, the very high “oﬀ” scores found in some patients may
be a manifestation of particularly advanced degenerative dis-
ease, which may not be amenable to a neuroprotective gene
therapy.
The therapeutic target may also impact upon the choice
of outcome measures, depending on which symptoms the
therapy intends to alleviate, that is, motor or nonmotor, and
whether it aims to slow the rate of progress of the disease.
Further diﬃculties will be experienced during prolonged
gene therapy trials; as the clinical condition progresses, it is
likely that a proportion of enrolled patients will require esca-
lationoftherapiestoincludeDBSorinfusedtherapies,which
willmakedissectingoutthespeciﬁctherapeuticcontribution
from gene therapy challenging.
10. Discussion
Genetherapyhasundergonearenaissancesincegenetherapy
trials were halted temporarily in 1999 when a patient died
from multiorgan failure after receiving an adenoviral vec-
tor gene therapy for ornithine transcarbamylase deﬁciency
[103]. Subsequent technical advances in vector design and
production, such as the three-plasmid system, as well as
improved regulatory frameworks and more extensive animal
studies have served to increase conﬁdence in clinical trials of
gene therapy both in principle and practice. By 2008, over 40
clinical trials of gene therapy had been approved by the US
Food and Drug Administration, mostly using AAV serotype
2[ 104].
The results of several phase I and II clinical trials using
AAV-based gene therapy in PD are available, and clinical
trials of one lentiviral agent, Prosavin, are ongoing [12, 59,
61–63]. The safety data from these studies are very en-
couraging with little evidence of serious adverse eﬀects
attributable to the therapeutic agents used. Longer term out-
comedatafromthesestudieswillprovideadditionalvaluable
data regarding the safety of gene therapy for PD when it
becomes available. Eﬃcacy data from the clinical trials of
gene therapy for PD have been mixed. Phase I studies using
AAV to deliver the genes for GAD and for NTN both ob-
served signiﬁcant positive eﬀects on UPDRS motor scores in
the months following the intervention. Unfortunately, the
phase II randomised-controlled trial of AAV-NTN failed to
ﬁndasigniﬁcantdiﬀerenceinprimaryendpointcomparedto
controls, though there were improvements in some second-
ary outcome measures [12].
The recently published data from the randomised-con-
trolled phase II trial of AAV-GAD in PD patients demon-
strated signiﬁcant improvement in the primary outcome
selected, the reduction in oﬀ-medication UPDRS score from
baseline to 6 months, in patients undergoing intervention
rather than sham surgery control [62]. This was the ﬁrst suc-
cessfulrandomised-controlledtrialofgenetherapyforaneu-
rological disorder and, in addition to bringing gene therapy
for PD a step closer, there are broader implications for other
neurological disorders. For example, the AAV-GAD trial
serves as proof of principle for gene therapy in central ner-
vous system disorders such as the AAV-based gene therapy
trialsinCanavandisease,araretypeofleukodystrophy[101].
Gene therapy strategies for the treatment of PD are
becoming increasingly more sophisticated and the impor-
tance of trial design in this ﬁeld is readily apparent. This has
helped to meet some of the challenges inherent in targeting
gene therapy to a degenerative central nervous system disor-
der,includingvectordeliverytotheappropriatebrainregion,
avoidance of neurotoxicity of and identiﬁcation a suitable
molecular target. Future clinical trials of gene therapy for PD
are likely to be have a longer duration of followup, particu-
larly if neuroprotection is the proposed mechanism of action
of the transgene, and they would beneﬁt from a broader
range of validated outcome measures. In addition to oﬀering
a promising new treatment modality for a debilitating and
incurable disease, the lessons being learned in the hunt for
an eﬀective gene therapy for Parkinson’s disease oﬀer insight
intothepotentialofgenetherapyasapracticalandattainable
goal in a range of other neurological disorders.
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